Medicus Pharma Ltd. Common Stock cash flow to debt ratio of -570.04% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Medicus Pharma Ltd. Common Stock's free cash flow has decreased 122.27% from $-10.25M last year to $-22.78M, signaling decreasing performance

Medicus Pharma Ltd. Common Stock's debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability.

Medicus Pharma Ltd. Common Stock's debt has increased relative to shareholder equity from 0.10 last year to 0.13 today, signaling weakened financials

Medicus Pharma Ltd. Common Stock has a net cash position, so leverage is healthy.

Medicus Pharma Ltd. Common Stock's interest coverage ratio of 198.27 indicates that earnings with good margin can cover interest payments on company debt

Medicus Pharma Ltd. Common Stock has insufficient data to evaluate this check.

Medicus Pharma Ltd. Common Stock's short-term liabilities of $9.94M exceed its short-term assets of $9.89M, signaling financial risk

Medicus Pharma Ltd. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Medicus Pharma Ltd. Common Stock's return on equity of -4.09K%, is lower than 15.00%, indicating bad performance

Medicus Pharma Ltd. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Medicus Pharma Ltd. Common Stock has insufficient public price history to evaluate earnings stability.

Medicus Pharma Ltd. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it

Medicus Pharma Ltd. Common Stock has negative free cash flow, indicating cash burn

Medicus Pharma Ltd. Common Stock's yearly earnings has decreased 127.39% since last year from $-11.16M to $-25.37M, signaling decreasing performance

Medicus Pharma Ltd. Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -2.19K% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Medicus Pharma Ltd. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.

Medicus Pharma Ltd. Common Stock has insufficient public price history to evaluate revenue consistency.

Medicus Pharma Ltd. Common Stock has insufficient public price history to evaluate ROE consistency.

Medicus Pharma Ltd. Common Stock has insufficient data to evaluate this check.

Medicus Pharma Ltd. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Medicus Pharma Ltd. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Medicus Pharma Ltd. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Medicus Pharma Ltd. Common Stock has insufficient data to evaluate this check.

Medicus Pharma Ltd. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Medicus Pharma Ltd. Common Stock has a price-to-book ratio of 6.66x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Medicus Pharma Ltd. Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue